Axsome Therapeutics Inc

NASDAQ:AXSM  
31.69
+0.18 (+0.57%)
Products

Axsome Therapeutics Announces FDA Acceptance Of NDA For Migraine Treatment

Published: 09/14/2021 11:29 GMT
Axsome Therapeutics Inc (AXSM) - Axsome Therapeutics Announces FDA Acceptance of New Drug Application for Axs-07 for the Acute Treatment of Migraine.
Axsome Therapeutics Inc - FDA Has Set a PDUFA Target Action Date of April 30, 2022 for NDA.